Please login to the form below

Not currently logged in

varicose veins

This page shows the latest varicose veins news and features for those working in and with pharma, biotech and healthcare.

UK Biobank generates “largest open access resource of exome data”

UK Biobank generates “largest open access resource of exome data”

These include new links with specific genes to a higher risk of certain diseases, such as the PIEZO1 gene and varicose veins, the MEPE gene and bone mineral density and osteoporosis

Latest news

  • BTG rises on FDA approval of varicose vein therapy BTG rises on FDA approval of varicose vein therapy

    More than 30 million adults in the US aged 18 to 70 have varicose veins, with women twice as likely as men to develop them. ... We believe [Varithena] sets a new standard for the treatment of both the symptoms and appearance of varicose veins," commented

  • Nip and tuck

    NHS. The NHS Standard Contract makes it necessary for hospitals to provide PROMs for hips, knees, hernias and varicose veins operations.

  • Slim pickings

    Type 2 diabetes mellitus . Japan. Polidocanol  . Asclera (Merz Aesthetics). Varicose veins .

  • Merz acquire BioForm Medical

    BioForm, which went public in late 2007, specialises in injectable drugs to improve the appearance of the skin, including treatment of wrinkles and folds, as well as varicose veins.

  • Rumour mill

    a treatment for varicose veins, after it failed to find a partner to help fund the study.

More from news
Approximately 1 fully matching, plus 8 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs


Add my company
An agency called Owen

We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....

Latest intelligence

Virtual meeting technologies for reducing emissions and waste in the healthcare industry
Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...